10.06.26 -- Inside Scaling Next-Gen MSCs Without Scaling Risk

N-1 perfusion increases inoculum density and speeds production without altering fed-batch processes. Discover a practical path to lower costs and higher yields in biologics manufacturing.

Explore a scalable RNA-seq approach that delivers reproducible, high-quality transcriptomic data from checkpoint-edited T-cells, uncovering gene expression changes linked to PD-1 and TIGIT deletion.

See how CRISPR-generated FKRP knockout muscle cells and a high-throughput On-Cell Western method can quantify α-dystroglycan glycosylation restoration and support rAAV-FKRP potency testing.

Cell culture freezing requires precise fluid controls to safeguard viability. Examine advanced fluid management methods for cell banking, cell therapy, and large-scale cryogenic workflows.

Scale plays a pivotal role in viral vector economics. Compare intermediate-scale AAV and LV manufacturing scenarios to pinpoint effective strategies for reducing risk and total cost.

Scaling up lipid nanoparticles requires evaluating key fluid dynamics. Compare the trade-offs between laminar microfluidics and turbulent mixing to select the right scale-up strategy.

Engineered exosomes displaying tumor-homing peptides offer a promising tool for targeted cytotoxic drug delivery. See how stirred-tank bioreactor systems scale production efficiently for critical research.

Endonucleases are essential for clearing DNA impurities in viral vector manufacturing. Learn how a new enzyme compares to other commercially available options in AAV and LVV production.

Legacy biomanufacturing relies on rigid, custom operations. Modular automation, integrated sensors, and plug-and-produce designs create adaptable, efficient facilities.

Rigorous multi-cycle stress testing and environmental validation ensure manufacturing hardware delivers uncompromising reliability for critical processing workflows.

Traditional plasmid DNA manufacturing introduces biological impurities and structural variability that lower viral titers. Transitioning to cell-free synthetic DNA platforms ensures sequence fidelity.

Operational consistency across global facilities protects product integrity and supports growth. Standardized processes reduce risk, minimize variability, and strengthen quality across markets.

Commercializing lentiviral therapies requires robust expression. Review performance data from suspension cell lines using transient transfection in chemically-defined, animal-free media.

Explore how AI can be safely and effectively deployed in regulated pharma environments, with practical guidance on risk, governance, and lifecycle management rooted in GAMP 5 principles.